Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 or older at the time of their cancer diagnosis
• People diagnosed with a specific type of ovarian, fallopian tube, or peritoneal cancer (high-grade serous or endometrioid) who had a validated genetic tumour test (such as MyChoice HRD, FoundationOne DX, or a similar approved test) performed between January 2021 and January 2026
• People whose tumour test showed a high HRD score (above 42) or high LOH result, indicating a DNA repair deficiency, and who were treated with Bevacizumab and Olaparib after first-line platinum-based chemotherapy — these people may be enrolled in Cohort A
• People whose tumour test showed a low HRD score (below 42) or low LOH result, indicating normal DNA repair, and who were treated with first-line platinum-based chemotherapy with or without Bevacizumab or other targeted medicines — these people may be enrolled in Cohort B
• People who are able to understand the study procedures and are willing to provide written consent to participate

Who may not be able to join:

• People who have not had a validated genetic DNA repair test performed on a tumour sample
• People who have a BRCA1 or BRCA2 gene mutation (either inherited or developed in the tumour)
• People who have passed away at the time of enrolment into the study

Important: Always verify eligibility with the trial site directly before applying.